Compare AbbVie Inc (ABBV) vs Air Products & Chemicals, Inc. (APD) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

APD trades at $305.05, down 2.91% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, though 2025 saw a net loss of $394.50 million. Recent strategic moves include exiting the Louisiana Clean Energy Complex and finalizing a renewable ammonia deal with Yara, signaling a refined growth focus.

The outlook is positive with a consensus price target of $324.89, implying 6.5% upside. Risks include high debt levels and volatile cash flows from heavy investments. Investors should weigh the company's long-term growth projects against near-term financial pressures and geopolitical uncertainties affecting supply chains.